Avelos Therapeutics is a synthetic lethality-specialized anti-cancer drug development company currently developing anti-cancer drugs targeting substances involved in DNA damage response, cell cycles, and more
Total raised: $12.41M
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.05.2024 | Series B | $12.41M | - |
Mentions in press and media 4
| Date | Title | Description |
| 31.05.2024 | Avelos Therapeutics Secures Significant Funding to Advance Cancer Drug Development | Avelos Therapeutics, a pioneering company at the forefront of anti-cancer drug innovation, recently concluded a highly successful Series B funding round, raising an impressive total of KRW 30 billion. This substantial investment, spearheade... |
| 29.05.2024 | AVELOS THERAPEUTICS ANNOUNCES KRW 17 BILLION SERIES B FUNDING ROUND, SURPASSING KRW 30 BILLION TOTAL RAISED | Stassets Investment Leads Round with Major Contribution, Joined by LSK Investment and Shinhan Capital Investment Provides Crucial Resources for Company's Focus on Developing Small Molecule Synthetic New Drugs in Synthetic Lethality, DNA Dam... |
| 29.05.2024 | AVELOS THERAPEUTICS ANNOUNCES KRW 17 BILLION SERIES B FUNDING ROUND, SURPASSING KRW 30 BILLION TOTAL RAISED | Stassets Investment Leads Round with Major Contribution, Joined by LSK Investment and Shinhan Capital Investment Provides Crucial Resources for Company's Focus on Developing Small Molecule Synthetic New Drugs in Synthetic Lethality, DNA Dam... |
| 22.08.2022 | Avelos Therapeutics Raises $8M in Series A Funding | Avelos Therapeutics, a Seoul, South Korea-based biotechnology company specializing in new drug discovery and development, raised $8M in Series A funding. The round was led by SV Investment, UTC Investment, Quad Investment Management, Timepo... |